JIA, treatment and possible risk of malignancies

Nature Reviews Rheumatology

Volumn 7, Issue 1, 2011, Pages 6-7

  Ruperto, Nicolino ^a   Martini, Alberto ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BIOLOGICAL THERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CAUSAL ATTRIBUTION; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; ENTERITIS; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; MELANOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; ADOLESCENT; CHILD; DRUG ANTAGONISM; DRUG COMBINATION; NEOPLASM; NOTE; PRESCHOOL CHILD;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; METHOTREXATE; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650990577     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.199     Document Type: Review

References (10)

1. Martini, A. & Lovell, D. J. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 69, 1260-1263 (2010).
2. FDA. early communication about an ongoing safety review of tumor necrosis factor (TnF) blockers (marketed as remicade, enbrel, humira, and cimzia). http://www.fda.gov/ [online], http://www. fda.gov/Drugs/ Drugsafety/ PostmarketDrugsafetyinformation forPatientsandProviders/Drugsafety informationforHeathcareProfessionals/ UCM070725 (2008)
3. Diak, P. et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 62, 2517-2524 (2010).
4. Smolen, J. s. et al. eULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964-975 (2010).
5. Cabral, D. A. & Tucker, L. B. Malignancies in children who initially present with rheumatic complaints. J. Pediatr. 134, 53-57 (1999).
6. Lehman, T. J. should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum. 62, 2183-2184 (2010).
7. Simard, J., Neovius, M., Hagelberg, s. & Askling, J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. doi:10.1002/art.27741.
8. Truckenbrodt, H. & Häfner, R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 29, 801-807 (1986).
9. Paediatric Rheumatology european society [online], http://www.pres.org. uk/ (2010).
10. Ruperto, n. & Martini, A. international research networks in pediatric rheumatology: the PRinTO perspective. Curr. Opin. Rheumatol. 16, 566-570 (2004).